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Renal transplantation has become one of the most common surgical procedures
performed to replace a diseased kidney with a healthy kidney from a donor.
It can help patients with kidney failure live decades longer. However, renal
transplantation also faces a risk of developing various blood disorders. The blood
disorders typically associated with renal transplantation can be divided into two
main categories: (1) Common disorders including post-transplant anemia (PTA),
post-transplant lymphoproliferative disorder (PTLD), post-transplant erythrocytosis (PTE),
and post-transplant cytopenias (PTC, leukopenia/neutropenia, thrombocytopenia, and
pancytopenia); and (2) Uncommon but serious disorders including hemophagocytic
syndrome (HPS), thrombotic microangiopathy (TMA), therapy-related myelodysplasia
(t-MDS), and therapy-related acute myeloid leukemia (t-AML). Although many
etiological factors involve the development of post-transplant blood disorders,
immunosuppressive agents, and viral infections could be the two major contributors
to most blood disorders and cause hematological abnormalities and immunodeficiency
by suppressing hematopoietic function of bone marrow. Hematological abnormalities
and immunodeficiency will result in severe clinical outcomes in renal transplant
recipients. Understanding how blood disorders develop will help cure these
life-threatening complications. A potential therapeutic strategy against post-transplant
blood disorders should focus on tapering immunosuppression or replacing myelotoxic
immunosuppressive drugs with lower toxic alternatives, recognizing and treating
promptly the etiological virus, bacteria, or protozoan, restoring both hematopoietic
function of bone marrow and normal blood counts, and improving kidney graft survival.
Keywords: renal transplantation, post-transplant blood disorders, immunosuppressive agents, viral infections,
bone marrow suppression, impaired hematopoiesis, clinical features, therapeutic strategy
Renal transplant or kidney transplant is surgical procedure to place a functioning kidney from a
donor into a patient with kidney failure. A renal transplant is often the best treatment option for
patients with end stage kidney failure. The successful renal transplant could offer enhanced quality
and duration of life, which make the recipients return to a more normal lifestyle and have more
control over their daily living. With the advent of new immunosuppressive drugs and improved
donor-recipient matching procedures, rates of serious complications following renal transplanta-
tion have fallen sharply in recent years. However, like any other type of surgery, kidney transplant
surgery carries a risk of significant complications. Some blood disorders may occur and develop
after renal transplantation. Common post-transplant blood disorders include post-transplant ane-
mia (PTA), post-transplant lymphoproliferative disorder (PTLD), post-transplant erythrocytosis
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(PTE), and post-transplant cytopenias (PTC, including leu-
copenia, thrombocytopenia, and pancytopenia). Uncommon but
serious blood disorders are hemophagocytic syndrome (HPS),
thrombotic microangiopathy (TMA), therapy-related myelodys-
plastic syndromes (t-MDS), and therapy-related acute myeloid
leukemia (t-AML) (Ardalan et al., 2008; Reindl-Schwaighofer
and Oberbauer, 2014). Understanding how these post-transplant
blood disorders occur and develop in renal transplant recipients
is critical for developing further therapeutic strategies for these
life-threatening hematological complications. In this review, we
discuss the etiology, pathogenetic mechanisms, clinical features
and current management of each blood disorder mentioned
above.
Post-Transplant Anemia (PTA)
PTA, as a common complication after renal transplantation, is
attracting more and more attention of urological community
(Augustine and Hricik, 2006). It is usually classified as acute
(within 6 months post-renal transplant) and chronic (more than
6months post-renal transplant). PTAmay persist or reoccur after
renal transplantation. It occurred at least once in 38.3%, and reoc-
curred in 42% of renal transplant recipients within 5 years (Yu
et al., 2010). PTA can be caused by several conditions in renal
transplant recipients, including renal allograft dysfunction, med-
ications [immunosuppressive agents, angiotensin-converting
enzyme (ACE) inhibitors, angiotensin II receptor antagonists,
and antiviral and antimicrobial medications], viral infections,
acute rejection, nutritional deficiency, and blood group ABO
incompatibility (Reindl-Schwaighofer and Oberbauer, 2014).
Post-transplant renal allograft dysfunction has been recog-
nized as a major cause of PTA. The incidence of PTA, which
increases over time after the transplants, is positively related to
the level of creatinine in the blood. When the serum creati-
nine level rises above 2 mg/dL, a poorly functioning kidney allo-
graft will result in reduced erythropoietin (EPO) production. The
higher the serum creatinine level, the higher the incidence of PTA
(Imoagene-Oyedeji et al., 2006). The EPO level is usually consis-
tent with kidney functions after the transplants. As renal function
deteriorates, renal EPO secretion will decrease, causing PTA in
renal transplant recipients. Anemia related to chronic kidney dis-
ease (CKD) is characterized by loss of endogenous EPO produc-
tion and/or EPO hyporesponsiveness/resistance in the patients
(Winkelmayer and Chandraker, 2008). In some patients with
delayed graft function (DGF) after the transplants, an increase
in EPO level can be observed. Such an increase is generally
not accompanied by an increased in hemoglobin level, and may
return to its original level in a short time. The EPO level is neg-
atively correlated with the hemoglobin levels, suggesting EPO
hyporesponsiveness/resistance in patients with PTA (Rostami
et al., 2012).
Chronical exposure to immunosuppressive agents has
been known to be an important factor in the development of
anemia after transplantation, which operates mainly through
direct suppression of erythropoiesis in bone marrow (Winkel-
mayer and Chandraker, 2008). Immunosuppressant agents
include antiproliferative agents [such as azathioprine (AZA),
mycophenolate mofetil (MMF), thiopurine methyltrans-
ferase (TPMT), and sirolimus], calcineurin inhibitors [such
as cyclosporine (CsA) and tacrolimus (FK-506)], induction
immunosuppressive agents [such as muromonab-CD3 (OKT3)],
and anti-thymocyte globulin (ATG) (Nguyen and Shapiro, 2014).
A standard immunosuppressive regimen in renal transplantation
consists of combination therapy with an antiproliferative agent,
an induction immunosuppressive agent, a calcineurin inhibitor,
and a corticosteroid. These drugs may result in an increased
incidence of PTA when they are used after the transplants
(Al-Khoury et al., 2006).
Among the immunosuppressive agents, the antiproliferative
agents (AZA and MMF) and the calcineurin inhibitor (FK-506)
are myelosuppressive drugs that cause potentially the suppres-
sion of bone marrow. PTA caused by these myelotoxic drugs
is generally associated with leukopenia and/or thrombocytope-
nia (Lee et al., 2009). Calcineurin inhibitors may indirectly
cause PTA via nephrotoxicity, microangiopathic hemolytic ane-
mia (MAHA) and/or hemolytic-uremic syndrome (HUS) (Ver-
goulas, 2006). Nephrotoxicity may occur after the application of
a calcineurin inhibitor that causes damage to the kidneys. This
condition will result in elevated blood levels of urea nitrogen
(BUN), creatinine, and electrolytes (such as potassium and mag-
nesium) (Paige and Nagami, 2009). MAHA results from platelet
aggregation and fibrin deposition in the damaged endothelium
of small vessels to form a fibrin mesh. The fibrin mesh causes
narrowing or obstruction of small blood vessels and increases
shear forces within these small vessels, thus leading to mechan-
ical destruction (intravascular fragmentation hemolysis) of the
red blood cells and schistocyte formation (Korin et al., 2012).
The immunosuppressant OKT3 has been associated with MAHA
(Kim et al., 2011). HUS is a condition resulting from destruc-
tion of red blood cells that clogs the filtering system in the
kidneys. De novo HUS occurs often associated with the use
of CsA or OKT3 (Vergoulas, 2006), and may subsequently
induce hypertension, MAHA, TMA, and end-stage renal fail-
ure (Ardalan, 2006). Sirolimus is a non-nephrotoxic macrolide
antibiotic that reduces cytokine-dependent cellular proliferation
at the G1 to S phase of the cell-division cycle. It may inhibit
erythropoiesis by interfering with intracellular signaling path-
ways normally activated after the binding of erythropoietin to its
receptor, resulting in anemia, thrombocytopenia, and leucopenia
(Fang et al., 2007).
In addition, immunosuppressant drugs induce increased
susceptibility to virus such as parvovirus B19 (PVB19),
cytomegalovirus (CMV), and Epstein-Barr virus (EBV) in renal
transplant recipients, which cause aplastic anemia (Egbuna et al.,
2006). CMV and PVB19 infections have been reported in trans-
plant recipients with PTA and may cause pure red cell apla-
sia (PRCA) (Pinto et al., 2008). Viral infections (CMV, EBV,
influenza A, and human heprus virus 6 and 8) can also cause
HPS (a rare cause of PTA) and HUS in transplant recipients
(Asaka et al., 2000; Maakaroun et al., 2010). Some immuno-
suppressive agents (such as AZA, MMF, and FK-506) cause not
only the suppression of bone marrow, but also erythroblastope-
nia (PRCA) (Geetha et al., 2000). PRCA is an uncommon blood
disorder in which RBC maturation arrest occurs in the bone
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marrow. Erythroblasts are virtually absent, however, WBC and
platelet production is normal in bone marrow. The anemia due
to PRCA is a severe anemia, in which a reticulocyte count is
generally less than 1%, and mature erythroblasts present less
than 0.5% in the bone marrow (Fallahi et al., 2014). PRCA can
develop in patients with PVB19 infection (Kurukulasuriya et al.,
2011; Baral et al., 2012), erythropoietin therapy (Casadevall et al.,
2002; Macdougall et al., 2012), ABO-incompatible transfusion
(Rowley et al., 2011), and stem cell transplantation (Stussi et al.,
2009). PVB19 may cause PRCA due to its viral tropism and
direct cytotoxicity to erythroid progenitor cells (Heegaard and
Brown, 2002). PRCA can also be a result of therapy with cer-
tain recombinant forms of EPO, probably because of produc-
tion of neutralizing antibodies that inhibit the erythropoietic
activity of endogenous EPO and recombinant erythropoiesis-
stimulating agents (ESAs) (Casadevall, 2005). PRCA can further
develop into aplastic anemia and acute myelogenous leukemia,
which are life threatening illnesses for patients (Clark et al.,
1984). High-dose intravenous immunoglobin therapy should be
considered for PRCA caused by PVB19 infections and erythro-
poietin therapy. PRCA may be reversible by immunoglobulin
within a few months (Kurukulasuriya et al., 2011; Baral et al.,
2012).
Both ACE inhibitors and angiotensin II (ATII) receptor antag-
onists have an inhibitory action on the generation of red blood
cells in renal transplant patients. The use of these drugs in renal
transplant recipients can cause PTA, especially in the patients
with post-transplant renal failure (Chhabra et al., 2008). The
mechanisms by which ACE inhibitors and ATII receptor antag-
onists cause PTA, include inhibition of endogenous erythropoi-
etin production, inhibition of ATII-mediated stimulation of red
blood cell precursors (Macdougall, 1999), and the generation of
an erythropoiesis-inhibiting protein by ACE inhibitors (Henrik-
sen and Jacob, 2003). In addition, the application of antiviral
(Chhabra et al., 2008), antimicrobial (Reindl-Schwaighofer and
Oberbauer, 2014), and antilymphocyte (Jordan et al., 1999) drugs
[such as ganciclovir, trimethoprim-sulfamethoxazole, antilym-
phocyte globulin (ALG)] have been reported to cause PTA in
renal transplant recipients.
PTA can also be caused by transplant rejection and nutri-
tional deficiencies. Acute rejection results in a sharp decrease
in erythropoietin production and anemia at the early stage of
renal transplantation (Galutira and Del Rio, 2012). Transplant
rejection also causes systemic inflammatory response syndrome
in renal transplant recipients. It disturbs the binding of iron
to folic acid and blocks their transport, thus leading to PTA.
In pediatric renal allograft recipients with acute rejection, an
“erythropoiesis cluster” of 11 genes involved in hemoglobin
(Hb) transcription and synthesis, iron and folate binding, and
transport were found to be downregulated (Chua et al., 2003).
TMA that may develop during episodes of severe vascular rejec-
tion, is another mechanism for the development of PTA during
rejection (Barbour et al., 2012). Once acute rejection is con-
trolled, the EPO secretion can be restored to normal level. Post-
transplant nutritional deficiencies such as iron deficiency, folic
acid deficiency, and vitamin B6/B12 deficiency result in PTA
due to a lack of nutrients needed for blood cell production
(Chadban et al., 2010). PTA caused by iron deficiency is gener-
ally associated with blood loss during dialysis or the operative
procedure, excessive collection of blood samples prior to trans-
plantation, abnormal coagulation related to renal failure, and
post-operative gastrointestinal bleeding (Galutira and Del Rio,
2012).
Blood group ABO-incompatible transplantation is a medical
technique of allocating human organs for transplantation. This
innovative desensitization technique can eliminate a recipient’s
reaction to an incompatible blood type, and permits more effi-
cient use of available organs regardless of ABO blood type that
will otherwise be unavailable due to hyperacute rejection (West
et al., 2006). However, ABO-incompatible transplantation can
cause significant hemolysis or hemolytic anemia in transplant
recipients. Hemolysis following ABO-incompatible transplanta-
tion is caused by a type of graft-vs.-host reaction in which the
B-lymphocytes in the donor organ produce ABO antibodies (typ-
ically immunoglobulin G) to the ABO antigens of the recipient.
Hemolysis occursmore often in the blood group type A recipients
(Maheshwari et al., 2004). ABO-incompatible kidney transplan-
tation is also associated with PTLD and renal failure (Nose et al.,
2012).
Recent studies have shown that PTA is commonly asso-
ciated with post-transplant CKD or called chronic allograft
nephropathy (CAN) in renal transplant recipients. It might
begin to develop in the early stages of CKD, and might tend
to worsen as CKD progresses (Brugnara and Eckardt, 2011;
Choukroun et al., 2012). In addition, PTA is also probably the
most common risk factor that causes cardiovascular diseases
(such as de novo congestive heart failure and left ventricular
mass) and the death of renal transplant recipients (Winkelmayer
and Chandraker, 2008). Therefore, appropriate treatment for
PTA is important for slowing post-transplant CKD progression
and preventing cardiovascular complications in renal transplant
recipients.
The goals of therapy for PTA should be to restore EPO pro-
duction, to maintain hemoglobin at an adequate level, to enhance
kidney graft survival, and to treat underlying cardiovascular dis-
orders (Malyszko et al., 2012). ESAs are recommended to treat
anemia resulting from chronic kidney failure, chemotherapy, cer-
tain treatments for Human Immunodeficiency Virus (HIV), and
also to reduce the number of blood transfusions during and
after certain major surgeries (Hung et al., 2014). ESAs include
EPO, epoetin alfa (Procrit/Epogen), epoetin beta (NeoRecor-
mon), darbepoetin alfa (Aranesp), and methoxy polyethylene
glycol-epoetin beta (Mircera). These agents work by stimulat-
ing the bone marrow to produce red blood cells and maintaining
hemoglobin at the lowest level. ESAs have been proven effective
at correcting PTA after renal transplantation (Locatelli and Del
Vecchio, 2011). Correction of PTA with ESAs (such as EPO and
epoetin beta) has a beneficial effect on slowing post-transplant
CKD progression and improving quality of life in renal transplant
recipients. The application of high doses of ESAs in renal trans-
plant recipients can obviously improve physiological function
and glomerular filtration rate (GFR) of the grafted kidneys, thus
reducing the incidence of endstage renal disease and enhancing
long-term kidney graft survival (Choukroun et al., 2012).
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Post-Transplant Lymphoproliferative
Disorder (PTLD)
PTLD is a well-recognized complication of both solid organ
transplantation (SOT) and allogeneic hematopoietic stem cell
transplantation (HSCT). In renal transplant recipients, PTLD is
usually caused by EBV infection due to therapeutic immuno-
suppression after renal transplantation (Newstead, 2000). EBV
is a herpes virus that latently infects B-cell lymphocytes and
chronically replicates in the cells of the oropharynx (Comoli
et al., 2005). In normal condition, EBV infection activates innate
immunity (both humoral and cellular immunity) to control EBV
replication and proliferation of EBV-infected B-cells. However,
when immunosuppressants such as FK-506 and CsA are used
to prevent graft rejection after renal transplantation, these drugs
will impair CD4 and CD8 T-cell immunity by inhibiting T cell
function, thus leading to uncontrolled proliferation of EBV-
infected B-cells to form lymphoid hyperplasia or B cell lym-
phoma (Kamaleshwaran et al., 2014). Depletion of T cells by
use of anti-T cell antibodies (ATG, ALG, and OKT3) to pre-
vent or treat transplant rejection may also increases the risk of
developing PTLD.
Themolecular pathogenesis of PTLD caused by EBV infection
may involve genetic or epigenetic alterations of several cellular
genes, such as translocations (involving C-MYC, IGH, BCL-2,
BCL-6), various copy number variations, DNAmutations (PIM1,
PAX5, p53, C-MYC, RhoH/TTF), DNA hypermethylation, and
polymorphisms in both the host cell’s genome (IFN-gamma, IL-
10, TGF-beta, HLA) and the EBV genome (Capello and Gaidano,
2009). As a consequence of defects in the DNA mismatch repair
mechanism, microsatellite instability in the tumormicroenviron-
ment seems to play an important role in the development of
PTLD, which allows antitumor immune responses even in an
immunocompromised host (Capello et al., 2005; Morscio et al.,
2013).
Most cases of PTLD usually occur with 1–2 months of organ
transplant. The incidence rate of PTLD varies between 1 and
5% in renal transplant recipients (Preiksaitis, 2004). There is an
increased risk of PTLD in the patients with a negative EBV-
specific test result before kidney transplantation, as compared
to those with a positive EBV-specific test result. In addition, if
renal transplantation is performed in children less than 5 years of
age, a marked increase in the incidence of PTLD can be observed
(Allen et al., 2001). PTLD is often aggressive, rapidly progressive,
and potentially life threatening. Its related mortality ranges from
25 to 26.6% (Wasson et al., 2006). The patients with PTLD may
develop infectiousmononucleosis-like lesions or polyclonal poly-
morphic B-cell hyperplasia (Zimmermann and Trappe, 2011).
PTLD often spread to organs or tissues (the lung, gastrointestinal
tract, and central nervous system) outside of the lymph nodes.
Clinical presentation of PTLD is variable and includes: an acute
infectious mononucleosis-like disease with marked constitu-
tional upset and rapid enlargement of tonsils and cervical nodes,
a fulminant presentation that presents with widespread infiltra-
tive disease with multi-organ involvement, isolated or multiple
tumors involving the allograft, gastrointestinal symptoms, and
pulmonary nodules (Loren et al., 2003).
The typical histopathological changes of PTLD could be a
large increase in the number of B cell lymphocytes in lymphoid
tissues, accompanied by multiple focal areas of necrosis (Elmore,
2006). The lesion may include plasmacytic hyperplasia, B-cell
hyperplasia, B-cell lymphoma, or immunoblastic lymphoma.
Histopathological evidence for the presence of EBV DNA, RNA,
or protein is very important to make an accurate diagnosis of
PTLD, and can be obtained by using immunohistologic stain-
ing of paraffin-embedded tissue, In situ hybridization with the
EBV-encoded RNA probe, and qualitative and quantitative EBV
polymerase chain reaction (PCR) (Gulley, 2001). Qualitative and
quantitative EBV PCR is the most commonly used laboratory
test for the monitoring of the EBV viral load in the peripheral
blood of the recipients and for the diagnosis of PTLD after renal
transplantation. EBV viral load measurement in peripheral blood
mononuclear cells (PBMCs) and serum samples using quantita-
tive and quantitative PCR techniques has been proven to be a
powerful diagnostic tool to monitor transplanted patients at risk
to develop PTLD (Merlino et al., 2003). Because healthy trans-
plant recipients usually have low EBV viral loads in the peripheral
blood, high EBV loads may be strongly associated with current or
impending PTLD (Gulley and Tang, 2010). A trend of EBV PCR
values changed over time is more valuable in making a reliable
diagnosis of PTLD. Declines in EBV loads may be associated with
response to therapeutic interventions (such as immunosuppres-
sion tapering, rituximab therapy, and chemotherapy) (Tsai et al.,
2002).
PTLD may spontaneously regress with tapering immunosup-
pressive therapy (reduction or cessation of immunosuppressive
treatment). Immunosuppression tapering can lead to hemato-
logical remission and attenuation of symptoms associated with
PTLD (Karras et al., 2004). However, immunosuppression taper-
ingmay not always have benefits to the renal transplant recipients
because reduction of immunosuppression increases the risk of
inducing allograft dysfunction or loss. Other potential treatments
include (1) immunomodulator agent (rituximab), (2) passive
immunization with anti-EBV monoclonal antibodies (anti-B-
cell monoclonal antibody, anti-CD21 antibody, or anti-CD24
antibody), (3) antiviral therapy against CMV (acyclovir, valacy-
clovir, ganciclovir, or foscarnet), (4) interferon alfa-2b (Intron
A) therapy, (5) T-cell–based therapy (EBV-specific cytotoxic T
lymphocytes), (6) intravenous gamma globulin (IVIG) therapy
(gamimune, gammagard S/D, sandoglobulin), (7) antineoplas-
tic agents (prednisone, cyclophosphamide, doxorubicin, vin-
cristine,etc.), (8) combination chemotherapy (rituximab followed
by cyclophosphamide, adriamycin, oncovin, and prednisone), (9)
surgery excision, and (10) localized radiation therapy (Weikert
and Blumberg, 2008).
Rituximab, an IgG1 kappa immunoglobulin, is an engi-
neered chimeric murine/human monoclonal antibody that con-
tains murine heavy and light chain variable regions directed
against both the CD20 antigen found on pre-B lymphocytes and
mature B lymphocytes and the human IgG1 constant region.
It can block proliferating, apoptosis and lysis of B lympho-
cytes through complement-dependent cytotoxicity, antibody-
dependent cell cytotoxicity, and activation of tyrosine kinases as
a direct effect of the antibody binding to its CD20 ligand (Jain
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et al., 2005). Rituximab has been successfully used in the renal
transplant setting, to facilitate desensitization in both highly sen-
sitized transplant recipients and ABO-incompatible transplant
recipients, to treat CD20-expressing PTLD following renal trans-
plantation, to treat rejection associated with B cells and anti-
bodies, and to treat recurrent glomerular diseases in the renal
allograft (Barnett et al., 2013). Recent evidence indicates that
rituximab might be a safe and effective agent to treat PTLD,
with generally an overall response rate of 50–69% (Becker et al.,
2006; Salama and Pusey, 2006; Kahwaji et al., 2009). Interfer-
ons can modulate the response of the immune system to EBV,
control B cell proliferation, and promote TH1 response to virus.
Anti-EBV monoclonal antibodies may slow down the prolifer-
ation of B cell lymphocytes. Combination chemotherapy with
rituximab followed by CHOP (cyclophosphamide, adriamycin,
oncovin, and prednisone) is efficacious in the management of
PTLD and may be superior to rituximab monotherapy followed
by chemotherapy at the time of PTLD progression or relapse. The
therapies mentioned above may be effective in preventing clinical
deterioration in the condition of patients with PTLD (Martorelli
et al., 2012). Recently, a phase 2 study of adoptive transfer of
EBV-specific T cells has demonstrated high efficacy with minimal
toxicity (Louis et al., 2010).
Post-Transplant Erythrocytosis (PTE)
PTE is another common complication after renal transplan-
tation. It is defined as persistently elevated hemoglobin (Hb)
(>17 g/dL) and hematocrit (>51%) levels and persists for more
than 6 months (Einollahi et al., 2005; Kiberd, 2009). A signifi-
cant increase in hemoglobin and hematocrit levels will leads to
increased viscosity of the blood, causing thrombosis, hyperten-
sion and other complications (e.g., cerebral vascular accident) in
renal transplant recipients. PTE occurs in 10–20% of renal trans-
plant recipients and usually develops 8 to 24 months after the
transplants. Like other forms of erythrocytosis, the patients with
PTE often experiencemalaise, headache, plethora, lethargy, dizzi-
ness, and thromboembolism. Approximately 1–2% of patients
eventually die from complications related to PTE (Vlahakos et al.,
2003).
Multiple factors may be involved in the development of PTE.
Considerable evidence indicates that at least three hormonal
systems [EPO, the renin-angiotensin system (RAS), and endoge-
nous androgens] participate in the pathogenesis of PTE (Vla-
hakos et al., 2003). EPO is an essential glycoprotein hormone that
controls erythropoiesis (red blood cell production). It is mainly
produced by interstitial fibroblasts in the kidney in close asso-
ciation with peritubular capillary and tubular epithelial tubule.
In many cases of PTE, over-production of EPO is provoked by
the transplanted kidney. Endogenous EPO-release from the kid-
neys stimulates erythropoiesis (Jelkmann, 2011). Some factors
have been suggested to be involved in over-production of EPO
after the transplants, which include chronic rejection, renal artery
stenosis, cyclosporin, and hydronephrosis of the transplanted
kidney. These factors have been shown to cause PTE by induc-
ing renal ischemia and over-production of EPO (Abdelrahman
et al., 2004).
The RAS could be involved in the pathogenesis of PTE in
renal transplant recipients. RAS is a hormone system that regu-
lates blood pressure and erythropoiesis. Angiotensin II might be
responsible for inappropriately sustaining secretion of erythro-
poietin through directly stimulating the erythroid progenitors
within the bone marrow or augmenting the production of other
erythropoietic factors, thus increasing erythropoiesis. Enhanced
erythropoiesis can also be mediated by activation of the RAS via
angiotensin II AT1 receptor of kidney cells (Kato et al., 2005;
Park and Zambidis, 2009). Male gender is one important factor
predisposing to PTE. Androgens enhance sensitivity of primitive
erythrocytes to EPO, activating increased erythropoiesis in male
patients. This is the reason why PTE develops more frequently in
male patients than females (Yildiz et al., 2003).
Some non-EPO erythropoiesis-stimulating factors may either
enhance the sensitivity to EPO or directly promote erythro-
poiesis. An anomaly in insulin-like growth factor-1 (IGF-1) and
its binding proteins-1 and -3 have been accused to induce PTE
(Malyszko et al., 2012). The oligopeptide N-acetyl-seryl-aspartyl-
lysyl-proline (Ac-SDKP) is a natural inhibitor of hematopoietic
stem cell proliferation which is degraded mainly by ACE. Once
ACE is inhibited, Ac-SDKP will accumulate in plasma and cause
a decrease in erythropoiesis (Chen et al., 1992). After the trans-
plants, the kidney will start removing toxins from the body,
which progressively reduce bone marrow suppression caused by
the toxins. This may enhance hematopoietic function of bone
marrow and cause an increase in red blood cell production
(Gaciong et al., 1996). Other causes for an increased erythro-
poiesis, may include smoking, overnutrition, hypertension, and
diabetes (Ahmed et al., 2012).
The treatment goal for PTE is to lower Hb level below 17.5 g/dl
in normotensive patients. PTE can be effectively treated with
the RAS inhibitors including ACE inhibitors (such as capto-
pril, enalapril, lisinopril, fosinopril, peridropril, and ramipril),
and angiotensin II receptor antagonists (losartan, candesartan,
telmisartan, and valsartan) (Cruzado et al., 2008). Several other
drugs also showed efficacy in treatment of PTE in renal trans-
plant recipients: theophylline, a nonselective adenosine receptor
antagonist, can be used as an alternative mode of therapy of PTE;
ketanserin, an antagonist of peripheral 5-HT2 receptors, can
lower plasma erythropoietin levels in some chronic hemodialysis
patients; and sirolimus, an immunosuppressant agent that causes
marrow suppression and anemia, can be used to help treat PTE
(Charfeddine et al., 2008). To decrease the risk of thromboem-
bolic events, intermittent venesection (or phlebotomy) should be
performed in the PTE patients if their hemoglobin level cannot be
adequately lowered with medications or their hematocrit values
exceed 55% (Vlahakos et al., 2003).
Post-Transplant Cytopenias (PTC)
Cytopenia is a disorder in which the production of one or more
blood cell types ceases or is greatly reduced. This disorder is often
caused by immunosuppressive therapy, chemotherapy, and viral
infections after renal transplantation. Cytopenia include anemia
(adeficiency of RBCs), leukopenia or neutropenia (a deficiency
of WBCs or leukocytes), thrombocytopenia (a deficiency of
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platelets), and pancytopenia (a deficiency of all three blood cell
types—RBC, WBC, and platelet) (Smith, 2010).
Leukopenia or Neutropenia
Leukopenia is a common occurrence following organ transplan-
tation. It is defined as that a total WBC count is less than 3000–
4000 cells/µL. The most common form of leukopenia is neu-
tropenia which is an abnormally low count of neutrophils, and
generally defined as a count of 1500 or fewer cells/µL (Smith
et al., 2014). About 20–63% of kidney recipients will experience
at least one episode of leukopenia/neutropenia. It typically occurs
around day 100 after transplantation and can last from 1 to 4
weeks (Luan et al., 2011). The cause of leukopenia/neutropenia
is usually multifactorial. The most predictable immunosuppres-
sive agent to cause leukopenia/neutropenia is AZA, with 50%
of renal transplant recipients developing leukopenia/neutropenia
(Pollak et al., 1980). However, leukopenia/neutropenia due to
AZA is most often reversible with decrease or discontinuation
of the drug. T-cell depleting antibody therapies (thymoglobu-
lin, atgam, alemtuzumab, and basiliximab) can result in some
degree of leukopenia/neutropenia by eliminating targeted lym-
phocytes (Zaza et al., 2014). Leukopenia/neutropenia due to
the use of MMF is seen in 13–35% of renal transplant recip-
ients. The marrow effects of MMF are correlated with active
metabolite, mycophenolic acid (MPA). The anti-CMV myelo-
suppressive agents (valganciclovir and ganciclovir) have been
shown to cause leukopenia/neutropenia in 50% of transplant
patients in a dose-dependent manner (Brum et al., 2008). The
calcineurin inhibitors (CsA, FK-506, and sirolimus) are also
reported to increase the risk of hematologic toxicity and leukope-
nia/neutropenia (De Rycke et al., 2011). Several commonly
used antibiotics (such as trimethoprim-sulfamethoxazole, beta-
lactam antibiotics, and piperacillin) can be frequently impli-
cated as a possible etiology for leukopenia/neutropenia (Lee
et al., 2009). Deficiencies of some essential nutrients, such
as folic acid, vitamin B12, zinc, and copper, may also lead
to leukopenia/neutropenia (Munshi and Montgomery, 2000).
Viral infections have marked myelosuppression effects in renal
transplant recipients, and have been reported to have leukope-
nia/neutropenia as a manifestation, including CMV, PVB19,
herpesvirus-6 (HHV-6), influenza, and ehrlichiosis (Kotton and
Fishman, 2005).
There are no ideal therapies for leukopenia/neutropenia after
renal transplantation, but the most effective way to attenuate
leukopenia/neutropenia is to discontinue the most likely offend-
ing drugs (such as MMF, valganciclovir, CsA, and FK-506) or
cut down their doses. However, this strategy is frequently linked
to increase risk of rejection. Recombinant granulocyte-colony
stimulating factors (G-CSF), such as filgrastim (Neupogen),
may be effective in treating leukopenia/neutropenia cuased by
chemotherapy with valganciclovir or ganciclovir. G-CSF can be
considered a second-line of therapy after adjustment of the other
medications. In addition, stem cell transplants may be useful in
treating some types of severe leukopenia/neutropenia, including
those caused by the myelosuppressive agents (Hartmann et al.,
2008).
Thrombocytopenia
Thrombocytopenia is defined as that a total platelet count is
less than 50,000/µL. It is quite prevalent in the first year after
renal transplantation. Most renal recipients may show the low-
est platelet count in the first 3 months. The main clinical
manifestations of thrombocytopenia include the mild to seri-
ous bleeding, bruising, petechial, malaise, fatigue, and general
weakness (Xie et al., 2013). Thrombocytopenia often occurs as
a result of bone marrow suppression due to immunosuppres-
sant agents, infection, acute rejection episodes, chemotherapy,
antiplatelet antibody therapy, microangiopathy, or deficiencies
of folate and Vitamin B12 (Najean et al., 1997). The cause of
thrombocytopenia is usually overlapped with the causes of ane-
mia and leukopenia in renal transplant recipients. After the use
of sirolimus and/or calcineurin inhibitors, microangiopathy has
been reported as a cause of thrombocytopenia in renal trans-
plant recipients (Robson et al., 2003). Other medications that
cause thrombocytopenia include rabbit antithymocyte globulin,
valganciclovir, ganciclovir, linezolid, and heparin (Gabardi et al.,
2004). Viral infections, particularly CMV or EBV infection, can
cause thrombocytopenia and HPS (Torti et al., 2012).
The main concepts in treating thrombocytopenia are to dis-
continue suspected drugs that cause thrombocytopenia, to stimu-
late the bone marrow production of platelets, to maintain platelet
at an adequate level, and to treat microangiopathy (Provan et al.,
2010). In drug-induced thrombocytopenia, discontinuation or
alternatives of suspected drugs will be helpful in treating throm-
bocytopenia. Corticosteroids may be used to increase platelet
production. Lithium carbonate or folate may also be used to stim-
ulate the bone marrow production of platelets. Blood (platelet)
transfusions may be used to stop abnormal bleeding caused by
thrombocytopenia. Rituximab, daclizumab, and other new anti-
body preparations may be effective for patients with transplant
associated TMA. New generation thrombopoietin growth factors
(such as romiplostim and eltrombopag) have been used as sec-
ond line therapy of immune thrombocytopenia for hematopoi-
etic stem cell transplant patients (Wörmann, 2013), and may be
effective in treating post-transplant thrombocytopenia.
Pancytopenia
Pancytopenia, the deficiency of all three blood cell types (RBCs,
WBCs, and platelets), is characteristic of aplastic anemia, a poten-
tially life-threatening disorder that requires a stem cell trans-
plant. Pancytopenia has widespread effects on the entire body
by leading to oxygen shortage as well as problems with immune
function (Narang and Sachdeva, 2012). Pathologies involving
the WBC and platelet population often exist in the context of
pancytopenia, which can probably be a manifestation of sys-
temic infection (Marinella, 2010). In renal transplant recipi-
ents, PVB19 infection is a common cause of pancytopenia and
leads to various forms of glomerulopathy and allograft dysfunc-
tion (Yango et al., 2002). In addition, visceral leishmaniasis, a
disease caused by protozoan parasites of the genus Leishma-
nia and spread by the bite of certain types of sandflies, can
also cause pancytopenia in some immunocompromised renal
transplant recipients (Aardema et al., 2009). Other potential
factors involved in the development of pancytopenia include
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immunosuppressive drugs (azathioprine, MPA, anti-thymocyte
globulins, and alemtuzumab), chemotherapy drugs that cause
bone marrow suppression, antibiotics (linezolid and chloram-
phenicol), and radiation therapy (Nagasawa et al., 2004). Symp-
toms of pancytopenia can include bleeding, bruising, fatigue,
shortness of breath, and weakness. Treatments for pancytopenia
include drugs that suppress the immune system, bone marrow
stimulant drugs, blood transfusion, bone marrow transplant, and
stem cell replacement therapy (Narang and Sachdeva, 2012).
Other Hematological Complications of
Renal Transplantation
Uncommon but serious hematologic complications in the renal
transplant recipients include HPS, TMA, and therapy-related
myelodysplasia (t-MDS) and t-AML (Marinella, 2010). In renal
transplant recipients, the prognosis of these hematological com-
plications is usually severe, withmortality occurring inmore than
50% of patients (Mintzer et al., 2009).
Hemophagocytic Syndrome (HPS)
HPS, also referred as hemophagocytic lymphohistiocytosis
(HLH) or macrophage activation syndrome (MAS), is a clini-
copathologic entity characterized by uncontrolled proliferation
of hematophagic monocytes/macrophages/histiocytes that are
actively ingesting other blood cells. In most cases, HPS is asso-
ciated with opportunistic infection following intensive immuno-
suppression. HPS cases are observed not only in association with
viral infections [such as CMV, adenovirus, EBV, human herpes
virus 8 (HHV-8), human herpes virus 6 (HHV-6), PVB19, and
BK polyoma virus], but also with infections due to bacteria (such
as tuberculosis, Bartonella henselae, and Escherichia coli) and
protozoan (such as toxoplamosis, leishmaniasis, pneumocystis
carinii pneumonia, and babebiosis) (Karras et al., 2004; Ponti-
celli and Alberighi, 2009). Pathogenesis of post-transplant HPS
may involve (1) the activation of T helper-1 (Th-1) cells and the
overproduction of cytokines, tumor necrosis factor-alpha (TNF-
α) and interferon-gamma (IFN-γ) caused by severe infection, and
(2) abnormalities of CD8 + T lymphocyte and natural killer-
cell (NK-cell) cytotoxicity caused by immunosuppression. These
cellular and biochemical alterations may lead to excessive Th-1
lymphocyte and macrophage activation and uncontrolled prolif-
eration under lack of NK cell and T lymphocyte cytotoxicity, thus
causing hemophagocytosis (Ponticelli and Alberighi, 2009).
HPS usually develops in the first few months (35–61 days)
after renal transplantation, but in some recipients with para-
sitic infection or neoplasia it may occur years after transplanta-
tion. Generally, post-transplant HPS is associated with a higher
rate (53%) of death in renal transplant recipients (Gurkan et al.,
2006). Diagnostic criteria for HPS may include fever, cytopenia
of two lines, hypertriglyceridemia, hypofibrinogenemia, hyper-
ferritinemia (>500µg/L), hemophagocytosis, elevated soluble
interleukin-2 receptor (CD25), decreased NK-cell activity, and
hepato-splenomegaly (Ponticelli and Alberighi, 2009).
The main goal of therapy for HPS is to recognize promptly
and treat the etiological microorganism. Reduction or withdrawal
of immunosuppressive agents is usually recommended in order
to control infection. Intravenous methylprednisolone (Medrol)
may attenuate hemophagocytosis by reducing the activation of
macrophages and cytokines, but a prolonged administration may
worsen the underlying infection (Karras et al., 2004). CMV infec-
tion could be treated with intravenous ganciclovir resorting to
foscarnet or cidofovir. HHV-8 infection might be rescued by
reduction of immunosuppression and the administration of fos-
carnet. BK virus infection may be treated by withdrawal of
immunosuppressive therapy, infusion of intravenous IVIg and
increasing prednisone. The use of IVIg may also be useful for
treating bacteria and protozoan infections. In addition, graft
nephrectomy may be a possible therapeutic option for renal
transplant recipients with HPS resistant to standard supportive
therapy (Gurkan et al., 2006).
Thrombotic Microangiopathy (TMA)
TMA is a group of disorders characterized by thrombo-
cytopenia, MAHA (intravascular hemolysis and presence of
peripheral blood schistocytes), purpura, microvascular occlu-
sion (thrombi and coagulation) neurological symptoms, fever,
and renal dysfunction. HUS and thrombotic thrombocytopenic
purpura (TTP) are two major types of TMA (Barbour et al.,
2012). TMA is also a distinct and severe complication of
both renal transplantation and HSCT that are closely asso-
ciated with calcineurin inhibitors and often cause graft fail-
ure (Laskin et al., 2011). The calcineurin inhibitors (CsA and
FK-506) are directly toxic to microvascular endothelial cells
and can induce microvascular constriction and platelet aggre-
gation. Microvascular endothelial injury and platelet aggrega-
tion play an important role in the development of TMA in
renal transplant recipients. Intravascular thrombi of aggregated
platelets lead to thrombocytopenia and various degrees of organ
ischemia and anemia. Furthermore, viral infections (CMV, HIV,
and PVB19), severe renal ischemia and antibody-mediated acute
humoral rejection may also be implicated in TMA (Laskin et al.,
2011).
In renal transplant recipients, TMA may occur de novo (trig-
gered by immunosuppressive drugs and acute antibody-mediated
rejection) or recur in patients with previous history of HUS
(Noris and Remuzzi, 2010). The majority of de novo TMA cases
is related to calcineurin inhibitor therapy and occurs at a median
of 25 days after transplantation. Clinical features of de novo
TMA include anemia (hemoglobin <10 g/dL), thrombocytope-
nia, increased lactate dehydrogenase, decreased haptoglobin and
schistocytes (Caires et al., 2012). Calcineurin inhibitor with-
drawal or reduction should be the first step in the management of
post-transplantation TMA. Patients with systemic TMA need to
receive plasma therapy (fresh frozen plasma infusion or plasma-
pheresis), which is a procedure which replaces proteins necessary
for the complement cascade that the patient does not have (Noris
and Remuzzi, 2010). Some of these patients may also need dial-
ysis therapy (Caires et al., 2012). The targeted complement C5
inhibitor therapy (eculizumab for atypical HUS and rituximab
for TTP) is most likely to be effective in treating TMA (Barbour
et al., 2012). Rituximab (with or without cyclophosphamide) may
be efficacious as treatment for TTP (Laskin et al., 2011).
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Therapy-Related Myelodysplastic Syndromes
(t-MDS) and Acute Myeloid Leukemia (t-AML)
t-MDS (also known as myelodysplasia) is a hematological med-
ical condition with ineffective production of all blood cells. It
is characterized by blood cytopenias, ineffective hematopoiesis,
dyserythropoiesis, dysgranulopoiesis, dysmegakaropoiesis, and
increased myeloblast. The median time to development of t-
MDS is about 3–5 years (Bhatia, 2013). Patients with t-MDS
often develop severe anemia, cytopenias and refractory AML.
t-AML, also called acute myelogenous leukemia or acute non-
lymphocytic leukemia (ANLL), is a disorder of the myeloid
line of blood cells, characterized by the rapid growth of abnor-
mal white blood cells that accumulate in the bone marrow
and interfere with the production of normal blood cells. The
average time interval between onset of t-AML and receiving
organ transplantation is about 5 years. The symptoms of t-
AML include fatigue, shortness of breath, easy bruising and
bleeding, petechiae, bone and joint pain, and persistent or fre-
quent infections (such as gram-negative septicemia). t-AML pro-
gresses rapidly and the patients may die within weeks or months
if left untreated (Thalhammer-Scherrer et al., 1999). Both t-
MDS and t-AML are two treatment-related complications that
occur in organ transplant recipients treated with immunosup-
pressive agents. The two conditions are often associated with
heavy post-transplant immunosuppression by azathioprine (a
thiopurine prodrug) (Rashidi and Fisher, 2014) or by ATG
(Naithani et al., 2005). The ability of azathioprine to promote
clonal expansion of DNA mismatch repair (MMR)-deficient
myeloid cells is consistent with a role in the development of
t-MDS/t-AML in patients who have received organ transplants
(Bhatia, 2013).
Genetic variation in susceptibility to genotoxic exposures
[such as the use of chemotherapy agents (alkylating drugs),
epipodophyllotoxins and anthracyclines] increases significantly
the risk for development of t-MDS/t-AML. Chromosome 7
and/or 5 losses or deletions that are caused by alkylating
chemotherapy agents are related to the development of t-
MDS/t-AML. Variation on chromosome 7 and 5 may cause
translocations of chromosome bands 11q23 and 21q22 to encode
abnormal fusion proteins (transcription factors) and inhibit
myeloid differentiation(Bhatia, 2013). Furthermore, epigenetic
changes in DNA structure have been considered as a mech-
anism of t-MDS/t-AML. The loss of DNA methylation con-
trol due to a “differentiation arrest” in myeloid cells may lead
to uncontrolled growth of an immature clone of cells, thus
developing t-MDS/t-AML (Graubert and Walter, 2011; Lars-
son et al., 2013; Mazzarella et al., 2014). Other genetic, phar-
macological and radiotherapeutic factors, such as predisposing
factors (polymorphisms in detoxification and DNA repair
enzymes), granulocyte-colony-stimulating factor, topoisomerase
II inhibitors, and radiotherapy, may cause chromosome abnor-
malities (specifically del 5q,−7,+8, and del 20q) of bone marrow
cells. These factors also play a significant role in induction of
t-MDS/t-AML (Leone et al., 2007; Sebaa et al., 2012).
Discontinuing the use of azathioprine (Offman et al., 2004)
or replacing azathioprine with a nonthiopurine alternative (such
as mycophenolate, sirolimus, or everolimus) (Bhatia, 2013), has
been proven to reduce the incidence of post-transplantation
t-MDS/t-AML. Three DNA methyltransferase inhibitors (5-
azacytidine, decitabine, and lenalidomide) approved by the US
FDA for the treatment of t-MDS, can restore normal blood
counts and retard the progression of MDS to acute leukemia
by creating a more orderly DNA methylation profile in the
hematopoietic stem cell nucleus (Gore and Hermes-DeSantis,
2008). Supportive care with blood product support (RBC trans-
fusion), iron chelators (deferoxamine and deferasirox), and
hematopoeitic growth factors (erythropoietin), is the mainstay of
therapy for t-MDS/t-AM (Greenberg et al., 2011). Chemotherapy
with the hypomethylating agents (5-azacytidine and decitabine)
may help slow the progression of MDS to AML (Garcia et al.,
2010). Treatment for AML is usually divided into two phases:
induction and consolidation therapy. Induction therapy with
cytarabine (Ara-C) and anthracylines may achieve a complete
remission by reducing the number of leukemic cells to an unde-
tectable level. Consolidation therapy is the intensive chemother-
apy to eliminate any residual disease (Leahey et al., 1999).
After the completion of consolidation therapy, a combina-
tion immunotherapy with histamine dihydrochloride (INN) and
interleukin 2 can markedly reduce the risk of relapse in AML
and maintain remission of symptoms (Romero et al., 2009). For
patients with relapsed t-AML or t-MDS, HSCT can be considered
as a potentially curative therapeutic option (Kekre and Koreth,
2015).
Conclusions
Blood disorders after renal transplantation are frequently
observed. PTA, PTLD, PTE, and PTC are common hematological
complications, and HPS, TMA and t-MDS/t-AML are uncom-
mon but serious hematological complications in renal transplant
recipients. Multiple factors, including immunosuppressive drugs,
allograft dysfunction, viral or bacterial infections, antibiotics,
chemotherapy, decreased or increased EPO production, trans-
plant rejection episodes and nutritional deficiencies, are associ-
ated with the development of post-transplant blood disorders. Of
these etiological factors, chronical exposure to immunosuppres-
sive agents and subsequent viral infections can possibly be the
two major contributors to the post-transplant blood disorders.
Bone marrow suppression, which is typically due to the direct
effects of both immunosuppressive agents and viral infections,
is a fundamental cause of most blood disorders in renal trans-
plant recipients (Table 1 in Supplementary Material). A series
of molecular biological events, including genetic or epigenetic
alterations of cellular genes (DNAmutations, DNA hypermethy-
lation, or polymorphisms in DNA), DNAmismatch repair defect,
inhibition of hematopoietic stem cell proliferation, and chromo-
some abnormalities, have been proven to involve the develop-
ment of the drug or virus-induced bone marrow suppression.
As the direct consequences of myelosuppression, hematological
abnormalities, and immunodeficiency will cause severe clinical
outcomes (such as systemic infection symptoms, cardiovascular
diseases, renal allograft dysfunction or loss, CKD or CAN, and
death) in patients with post-transplant blood disorders. Pharma-
cological treatment strategies for post-transplant blood disorders
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should aim at tapering immunosuppressive therapy or replacing
myelotoxic immunosuppressive drugs with lower toxic alterna-
tives (e.g., ASTRAGRAF XL), recognizing and treating promptly
the etiological microorganism, attenuating bone marrow sup-
pression, restoring normal blood counts, retarding the progres-
sion of a blood disorder, enhancing kidney graft survival, and
treating underlying complications. Currently, there is an urgent
need to develop a new generation of immunosuppressant agents
that don’t cause myelotoxicity in renal transplant recipients. New
immunosuppressant drugs without myelotoxicity will have the
potential to decrease the incidence of blood disorders following
renal transplantation and to improve long-term kidney graft sur-
vival. HSCT can be considered as a potentially curative therapeu-
tic option for some types of blood disorders.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fcell.2015.
00018/abstract
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